J&J Reports Strong Q3 2023 Sales Growth Amid Diverse Business Performance
Johnson & Johnson (J&J; NYSE: JNJ) has released its Q3 2023 report, revealing impressive global...
Johnson & Johnson
J&J’s Cetrelimab and TAR-200 Gain Tacit Approvals for Bladder Cancer Trials
The Center for Drug Evaluation (CDE) website has indicated that Johnson & Johnson (J&J; NYSE:...
Janssen Unveils Promising Clinical Data on IL-23 Blockers for Psoriasis
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) is showcasing new clinical data...
J&J’s Janssen Reports Favorable Spravato Data in Late-Stage TRD Trial
Johnson & Johnson’s (J&J; NYSE: JNJ) subsidiary, Janssen, has presented tolerability and efficacy data from...
Janssen and Sanofi Partner for Development of First-in-Class E. coli Vaccine
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has entered into a strategic...
J&J and HHS Expand Public Health Initiative with Asha Therapeutics
Johnson & Johnson (J&J; NYSE: JNJ) and the US Department of Health and Human Services...
South Africa’s Competition Commission Investigates J&J for MDR-TB Drug Pricing and Evergreening
The Competition Commission of South Africa has announced an investigation into Johnson & Johnson (J&J;...
J&J Rebrands Pharmaceutical and MedTech Segments Post-Kenvue Separation
Following the completion of its consumer healthcare unit separation as Kenvue (NYSE: KVUE) last month,...
AbbVie’s Skyrizi Outperforms Janssen’s Stelara in Phase III Crohn’s Disease Trial
AbbVie (NYSE: ABBV) has announced early data from a Phase III trial that compared the...
Janssen Reports Positive Results from Phase Ib/II Study of Rybrevant Combo in EGFR-mutated NSCLC
Johnson & Johnson (J&J; NYSE: JNJ) subsidiary Janssen has provided an update on an ongoing...
Sandoz Inks Deal with Samsung Bioepis for Ustekinumab Biosimilar SB17
The Sandoz (SWX: SDZ) unit of Switzerland-based Novartis (NYSE: NVS) has announced the in-licensing of...
EMA Reviews Janssen’s Balversa for Advanced Urothelial Carcinoma with FGFR3 Alterations
The European Medicines Agency (EMA) has accepted for review a filing made by the Janssen...
Janssen’s Rybrevant Combo Meets Primary Endpoint in Advanced NSCLC Study
Janssen, a subsidiary of Johnson & Johnson (J&J; NYSE: JNJ), has released an update on...
Janssen Appoints Cherry Huang as President of Xi’an Janssen in China Management Shake-Up
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has announced a significant management...
Janssen Sues Distributors Over Counterfeit Antiretroviral Therapies in the US
Johnson & Johnson’s (J&J; NYSE: JNJ) subsidiary, Janssen, filed a lawsuit last week against pharmaceutical...
Johnson & Johnson Reports H1 2023 Sales Growth Following Kenvue Spinoff
Global healthcare giant Johnson & Johnson (J&J; NYSE: JNJ) has released a financial update for...
HHS Releases List of 10 Drugs for Medicare Price Negotiations Starting 2026
The Department of Health and Human Services (HHS) in the US has released a list...
Janssen Submits Indication Extension Application for Balversa in Urothelial Carcinoma Treatment
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has submitted an indication extension...
Janssen Submits Rybrevant for FDA Review as First-Line NSCLC Treatment
Johnson & Johnson (J&J; NYSE: JNJ) subsidiary Janssen has submitted an additional indication for review...
AstraZeneca Challenges US Government’s Drug Price Negotiation Plan for Medicare
UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has filed a legal claim against the US...